Evidence map›Paper›PMID 38543754›Full record

ArticleViruses2024

Impact of the H274Y Substitution on N1, N4, N5, and N8 Neuraminidase Enzymatic Properties and Expression in Reverse Genetic Influenza A Viruses.

Alexandre Gaymard, Caroline Picard, Guilhem Vazzoler, Pascale Massin, Emilie Frobert, Murielle Sabatier, Mendy Barthelemy, Martine Valette, Michèle Ottmann, Jean-Sébastien Casalegno and 2 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Alexandre GaymardVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.ORCID 0000-0002-8194-6126
Caroline PicardVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.ORCID 0000-0002-9214-3900
Guilhem VazzolerVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.
Pascale MassinAvian and Rabbit Virology Immunology and Parasitology Unit, National Reference Laboratory for Avian Influenza, Anses, Ploufragan-Plouzané-Niort Laboratory, BP53, F-22440 Ploufragan, France.ORCID 0000-0003-1182-0736
Emilie FrobertVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.
Murielle SabatierVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.
Mendy BarthelemyVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.
Martine ValetteCentre National de Référence des Virus des Infections Respiratoires, Groupement Hospitalier Nord, Hospices Civils de Lyon, F-69317 Lyon CEDEX 04, France.
Michèle OttmannVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.ORCID 0000-0002-6911-0705
Jean-Sébastien CasalegnoVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.ORCID 0000-0003-3271-9856
Bruno LinaVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.ORCID 0000-0002-8959-2123
Vanessa EscuretVirpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France.ORCID 0000-0002-5298-1002
Université Claude Bernard Lyon 1 · FRHospices Civils de Lyon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The H274Y substitution (N2 numbering) in neuraminidase (NA) N1 confers oseltamivir resistance to A(H1N1) influenza viruses. This resistance has been associated with reduced N1 expression using transfected cells, but the effect of this substitution on the enzymatic properties and on the expression of other group-1-NA subtypes is unknown. The aim of the present study was to evaluate the antiviral resistance, enzymatic properties, and expression of wild-type (WT) and H274Y-substituted NA for each group-1-NA. To this end, viruses with WT or H274Y-substituted NA (N1pdm09 or avian N4, N5 or N8) were generated by reverse genetics, and for each reverse-genetic virus, antiviral susceptibility, NA affinity (Km), and maximum velocity (Vm) were measured. The enzymatic properties were coupled with NA quantification on concentrated reverse genetic viruses using mass spectrometry. The H274Y-NA substitution resulted in highly reduced inhibition by oseltamivir and normal inhibition by zanamivir and laninamivir. This resistance was associated with a reduced affinity for MUNANA substrate and a conserved Vm in all viruses. NA quantification was not significantly different between viruses carrying WT or H274Y-N1, N4 or N8, but was lower for viruses carrying H274Y-N5 compared to those carrying a WT-N5. In conclusion, the H274Y-NA substitution of different group-1-NAs systematically reduced their affinity for MUNANA substrate without a significant impact on NA Vm. The impact of the H274Y-NA substitution on viral NA expression was different according to the studied NA.

Indexed as

Influenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza, HumanAmino Acid SubstitutionAntiviral AgentsDrug Resistance, ViralEnzyme InhibitorsHumansNeuraminidaseOseltamivirReverse GeneticsAntiviral AgentsEnzyme InhibitorsNeuraminidaseOseltamivirgroup-1 neuraminidasesH274Y-NA substitutionH275Y-NA substitutioninfluenza A virusesoseltamivir resistance

Identifiers

PMID38543754
PMCPMC10975200
OpenAlexW4392355347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.